The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis
<i>Background</i>. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with <i>BRAF</i>-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impac...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/1022 |
| _version_ | 1797570006502866944 |
|---|---|
| author | Fabio Gelsomino Andrea Casadei-Gardini Daniele Rossini Alessandra Boccaccino Gianluca Masi Chiara Cremolini Andrea Spallanzani Massimo Giuseppe Viola Ingrid Garajovà Massimiliano Salati Maria Teresa Elia Francesco Caputo Chiara Santini Alfredo Falcone Stefano Cascinu Emiliano Tamburini |
| author_facet | Fabio Gelsomino Andrea Casadei-Gardini Daniele Rossini Alessandra Boccaccino Gianluca Masi Chiara Cremolini Andrea Spallanzani Massimo Giuseppe Viola Ingrid Garajovà Massimiliano Salati Maria Teresa Elia Francesco Caputo Chiara Santini Alfredo Falcone Stefano Cascinu Emiliano Tamburini |
| author_sort | Fabio Gelsomino |
| collection | DOAJ |
| description | <i>Background</i>. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with <i>BRAF</i>-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impact of anti-angiogenics in patients with pre-treated <i>BRAF</i>-mutant CRC. <i>Methods.</i> We monitored patients in randomized, controlled studies who had advanced CRC and were undergoing second-line chemotherapy in addition to utilizing Bevacizumab, Ramucirumab or Aflibercept treatments. These data were pooled together with the data and results of <i>BRAF</i>-mutant patients enrolled in two phase III trials (TRIBE and TRIBE-2 study), who had been treated with second-line treatment both with or without Bevacizumab. Overall survival (OS), in relation to <i>BRAF</i> mutational status, was the primary focus. <i>Results</i>. Pooled analysis included 129 patients. Anti-angiogenics were found to have a significant advantage over the placebo in terms of OS (HR 0.50, 95%CI 0.29–0.85) (<i>p</i> = 0.01). <i>Conclusions</i>. Our pooled analysis confirms the efficacy of anti-angiogenics in pre-treated <i>BRAF</i>-mutant CRC, establishing the combination of chemotherapy plus Bevacizumab or Ramucirumab or Aflibercept as a valid treatment option. |
| first_indexed | 2024-03-10T20:19:06Z |
| format | Article |
| id | doaj.art-374b03a621794d8c9f536279dd2ebce7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T20:19:06Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-374b03a621794d8c9f536279dd2ebce72023-11-19T22:17:33ZengMDPI AGCancers2072-66942020-04-01124102210.3390/cancers12041022The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled AnalysisFabio Gelsomino0Andrea Casadei-Gardini1Daniele Rossini2Alessandra Boccaccino3Gianluca Masi4Chiara Cremolini5Andrea Spallanzani6Massimo Giuseppe Viola7Ingrid Garajovà8Massimiliano Salati9Maria Teresa Elia10Francesco Caputo11Chiara Santini12Alfredo Falcone13Stefano Cascinu14Emiliano Tamburini15Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121 Modena, ItalyDepartment of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121 Modena, ItalyDepartment of Translational Research and New Technologies in Medicine, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, 56121 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, 56121 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, 56121 Pisa, ItalyDepartment of Translational Research and New Technologies in Medicine, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, 56121 Pisa, ItalyDepartment of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121 Modena, ItalyDepartment of Surgery, Card. G. Panico Hospital of Tricase, 73039 Tricase, ItalyMedical Oncology Unit, University Hospital of Parma, 43121 Parma, ItalyDepartment of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121 Modena, ItalyDepartment of Medical Oncology, Card. G. Panico Hospital of Tricase, 73039 Tricase, ItalyDepartment of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121 Modena, ItalyDepartment of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121 Modena, ItalyDepartment of Translational Research and New Technologies in Medicine, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, 56121 Pisa, ItalyDepartment of Medical Oncology, Università Vita-Salute, San Raffaele Hospital IRCCS, 20019 Milan, ItalyDepartment of Medical Oncology, Card. G. Panico Hospital of Tricase, 73039 Tricase, Italy<i>Background</i>. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with <i>BRAF</i>-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impact of anti-angiogenics in patients with pre-treated <i>BRAF</i>-mutant CRC. <i>Methods.</i> We monitored patients in randomized, controlled studies who had advanced CRC and were undergoing second-line chemotherapy in addition to utilizing Bevacizumab, Ramucirumab or Aflibercept treatments. These data were pooled together with the data and results of <i>BRAF</i>-mutant patients enrolled in two phase III trials (TRIBE and TRIBE-2 study), who had been treated with second-line treatment both with or without Bevacizumab. Overall survival (OS), in relation to <i>BRAF</i> mutational status, was the primary focus. <i>Results</i>. Pooled analysis included 129 patients. Anti-angiogenics were found to have a significant advantage over the placebo in terms of OS (HR 0.50, 95%CI 0.29–0.85) (<i>p</i> = 0.01). <i>Conclusions</i>. Our pooled analysis confirms the efficacy of anti-angiogenics in pre-treated <i>BRAF</i>-mutant CRC, establishing the combination of chemotherapy plus Bevacizumab or Ramucirumab or Aflibercept as a valid treatment option.https://www.mdpi.com/2072-6694/12/4/1022colorectal cancerBRAF mutationanti-angiogenicschemotherapyMSI-H |
| spellingShingle | Fabio Gelsomino Andrea Casadei-Gardini Daniele Rossini Alessandra Boccaccino Gianluca Masi Chiara Cremolini Andrea Spallanzani Massimo Giuseppe Viola Ingrid Garajovà Massimiliano Salati Maria Teresa Elia Francesco Caputo Chiara Santini Alfredo Falcone Stefano Cascinu Emiliano Tamburini The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis Cancers colorectal cancer BRAF mutation anti-angiogenics chemotherapy MSI-H |
| title | The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis |
| title_full | The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis |
| title_fullStr | The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis |
| title_full_unstemmed | The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis |
| title_short | The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis |
| title_sort | role of anti angiogenics in pre treated metastatic i braf i mutant colorectal cancer a pooled analysis |
| topic | colorectal cancer BRAF mutation anti-angiogenics chemotherapy MSI-H |
| url | https://www.mdpi.com/2072-6694/12/4/1022 |
| work_keys_str_mv | AT fabiogelsomino theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT andreacasadeigardini theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT danielerossini theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT alessandraboccaccino theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT gianlucamasi theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT chiaracremolini theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT andreaspallanzani theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT massimogiuseppeviola theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT ingridgarajova theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT massimilianosalati theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT mariateresaelia theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT francescocaputo theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT chiarasantini theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT alfredofalcone theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT stefanocascinu theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT emilianotamburini theroleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT fabiogelsomino roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT andreacasadeigardini roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT danielerossini roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT alessandraboccaccino roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT gianlucamasi roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT chiaracremolini roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT andreaspallanzani roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT massimogiuseppeviola roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT ingridgarajova roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT massimilianosalati roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT mariateresaelia roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT francescocaputo roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT chiarasantini roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT alfredofalcone roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT stefanocascinu roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis AT emilianotamburini roleofantiangiogenicsinpretreatedmetastaticibrafimutantcolorectalcancerapooledanalysis |